114 related articles for article (PubMed ID: 37610850)
1. Enhancing the affinity of novel GLS1 allosteric inhibitors by targeting key residue Lys320.
Zhu L; Chang X; Zhang S; Bai X; Finko AV; Xu X; Bian J; Liu X; Huang H
Future Med Chem; 2023 Aug; 15(15):1393-1414. PubMed ID: 37610850
[No Abstract] [Full Text] [Related]
2. Synthesis of Novel Kidney-Type Glutaminase Allosteric Inhibitors Targeting the Critical Lys-320 Residue.
Song J; Pan C; Li J; Bai R; Zeng Z; Han Y; Chen Z; Hou W; Li Y; Ruan BH
ACS Med Chem Lett; 2023 Jan; 14(1):11-17. PubMed ID: 36655131
[TBL] [Abstract][Full Text] [Related]
3. Discovery of novel glutaminase 1 allosteric inhibitor with 4-piperidinamine linker and aromatic heterocycles.
Xu X; Chang X; Huang J; Zhang D; Wang M; Jing T; Zhuang Y; Kou J; Qiu Z; Wang J; Li Z; Bian J
Eur J Med Chem; 2022 Jun; 236():114337. PubMed ID: 35428013
[TBL] [Abstract][Full Text] [Related]
4. Structure-Enabled Discovery of Novel Macrocyclic Inhibitors Targeting Glutaminase 1 Allosteric Binding Site.
Xu X; Wang J; Wang M; Yuan X; Li L; Zhang C; Huang H; Jing T; Wang C; Tong C; Zhou L; Meng Y; Xu P; Kou J; Qiu Z; Li Z; Bian J
J Med Chem; 2021 Apr; 64(8):4588-4611. PubMed ID: 33792311
[TBL] [Abstract][Full Text] [Related]
5. Design, synthesis, and biological evaluation of novel glutaminase 1 allosteric inhibitors with an alkane chain tail group.
Chang X; Wang M; Zhang D; Zhang Y; Wang J; Li Z; Bian J; Xu X
Eur J Med Chem; 2023 Jan; 246():115014. PubMed ID: 36525694
[TBL] [Abstract][Full Text] [Related]
6. Design, synthesis, structure-activity relationship studies, and evaluation of novel GLS1 inhibitors.
Jo M; Koizumi K; Suzuki M; Kanayama D; Watanabe Y; Gouda H; Mori H; Mizuguchi M; Obita T; Nabeshima Y; Toyooka N; Okada T
Bioorg Med Chem Lett; 2023 May; 87():129266. PubMed ID: 37011768
[TBL] [Abstract][Full Text] [Related]
7. Development and Characterization of a Fluorescent Probe for GLS1 and the Application for High-Throughput Screening of Allosteric Inhibitors.
Xu X; Kuang Z; Han J; Meng Y; Li L; Luan H; Xu P; Wang J; Luo C; Ding H; Li Z; Bian J
J Med Chem; 2019 Nov; 62(21):9642-9657. PubMed ID: 31603674
[TBL] [Abstract][Full Text] [Related]
8. Targeting glutaminase 1 (GLS1) by small molecules for anticancer therapeutics.
Chen Y; Tan L; Gao J; Lin C; Wu F; Li Y; Zhang J
Eur J Med Chem; 2023 Apr; 252():115306. PubMed ID: 36996714
[TBL] [Abstract][Full Text] [Related]
9. Targeting GLS1 to cancer therapy through glutamine metabolism.
Yu W; Yang X; Zhang Q; Sun L; Yuan S; Xin Y
Clin Transl Oncol; 2021 Nov; 23(11):2253-2268. PubMed ID: 34023970
[TBL] [Abstract][Full Text] [Related]
10. Diselenide Covalent Allosteric Inhibitors of Glutaminase with Strong
Hou W; Chen Z; Pan C; Ni M; Ruan H; Song J; Lu S; Bhasin A; Ruan BH
ACS Med Chem Lett; 2023 Jul; 14(7):920-928. PubMed ID: 37465295
[TBL] [Abstract][Full Text] [Related]
11. An updated patent review of glutaminase inhibitors (2019-2022).
Wang D; Li X; Gong G; Lu Y; Guo Z; Chen R; Huang H; Li Z; Bian J
Expert Opin Ther Pat; 2023 Jan; 33(1):17-28. PubMed ID: 36698323
[TBL] [Abstract][Full Text] [Related]
12. miR-145 inhibits glutamine metabolism through c-myc/GLS1 pathways in ovarian cancer cells.
Li J; Li X; Wu L; Pei M; Li H; Jiang Y
Cell Biol Int; 2019 Aug; 43(8):921-930. PubMed ID: 31115975
[TBL] [Abstract][Full Text] [Related]
13. Design and structural optimization of thiadiazole derivatives with potent GLS1 inhibitory activity.
Okada T; Yamabe K; Jo M; Sakajiri Y; Shibata T; Sawada R; Yamanishi Y; Kanayama D; Mori H; Mizuguchi M; Obita T; Nabeshima Y; Koizumi K; Toyooka N
Bioorg Med Chem Lett; 2023 Sep; 93():129438. PubMed ID: 37549852
[TBL] [Abstract][Full Text] [Related]
14. Glutamine metabolism via glutaminase 1 in autosomal-dominant polycystic kidney disease.
Soomro I; Sun Y; Li Z; Diggs L; Hatzivassiliou G; Thomas AG; Rais R; Parker SJ; Slusher BS; Kimmelman AC; Somlo S; Skolnik EY
Nephrol Dial Transplant; 2018 Aug; 33(8):1343-1353. PubMed ID: 29420817
[TBL] [Abstract][Full Text] [Related]
15. GLS1 is a protective factor in patients with ovarian clear cell carcinoma and its expression does not correlate with ARID1A-mutated tumors.
Clemente V; Hoshino A; Shetty M; Nelson A; Erickson BK; Baker R; Rubin N; Khalifa M; Weroha SJ; Lou E; Bazzaro M
Cancer Res Commun; 2022 Aug; 2(8):784-794. PubMed ID: 36082022
[TBL] [Abstract][Full Text] [Related]
16. Targeting glutaminase 1 attenuates stemness properties in hepatocellular carcinoma by increasing reactive oxygen species and suppressing Wnt/beta-catenin pathway.
Li B; Cao Y; Meng G; Qian L; Xu T; Yan C; Luo O; Wang S; Wei J; Ding Y; Yu D
EBioMedicine; 2019 Jan; 39():239-254. PubMed ID: 30555042
[TBL] [Abstract][Full Text] [Related]
17. Structure-based virtual screening discovers novel kidney-type glutaminase inhibitors.
Lin LC; Chang HY; Lin TE; Lin JR; Hsia SM; Hsu KC; Huang TC
Biomed Pharmacother; 2022 Oct; 154():113585. PubMed ID: 36029536
[TBL] [Abstract][Full Text] [Related]
18. The role of GLS1-mediated glutaminolysis/2-HG/H3K4me3 and GSH/ROS signals in Th17 responses counteracted by PPARĪ³ agonists.
Miao Y; Zheng Y; Geng Y; Yang L; Cao N; Dai Y; Wei Z
Theranostics; 2021; 11(9):4531-4548. PubMed ID: 33754076
[No Abstract] [Full Text] [Related]
19. Novel allosteric glutaminase 1 inhibitors with macrocyclic structure activity relationship analysis.
Lee EJ; Duggirala KB; Lee Y; Yun MR; Jang J; Cyriac R; Jung ME; Choi G; Chae CH; Cho BC; Lee K
Bioorg Med Chem Lett; 2022 Nov; 75():128956. PubMed ID: 36038117
[TBL] [Abstract][Full Text] [Related]
20. Targeting glutaminolysis has antileukemic activity in acute myeloid leukemia and synergizes with BCL-2 inhibition.
Jacque N; Ronchetti AM; Larrue C; Meunier G; Birsen R; Willems L; Saland E; Decroocq J; Maciel TT; Lambert M; Poulain L; Hospital MA; Sujobert P; Joseph L; Chapuis N; Lacombe C; Moura IC; Demo S; Sarry JE; Recher C; Mayeux P; Tamburini J; Bouscary D
Blood; 2015 Sep; 126(11):1346-56. PubMed ID: 26186940
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
